About this trial

This study aims to evaluate the changes in metabolic parameters, intestinal permeability, and gastrointestinal symptoms in individuals who have undergone bariatric surgery (Laparoscopic Sleeve Gastrectomy - LSG) for obesity treatment.

Obesity is a chronic disease associated with serious health complications including type 2 diabetes, hypertension, cardiovascular disease, and metabolic disorders. Bariatric surgery is currently the most effective treatment method for morbid obesity. However, monitoring patients after surgery in terms of metabolic health, gut permeability, and gastrointestinal symptoms is crucial for long-term success.

In this study, 40 volunteers (aged 19-50) who have undergone LSG surgery within the last month will be followed for 6 months. At the beginning of the study and 6 months later, the following will be assessed:

* Metabolic parameters: fasting blood glucose, total cholesterol, triglycerides, high-density lipoprotein (HDL), low-density lipoprotein (LDL), very low-density lipoprotein (VLDL) cholesterol, and insulin levels * Intestinal permeability markers: zonulin, secretory immunoglobulin A (IgA), and lipopolysaccharide (LPS) levels * Gastrointestinal symptoms: assessed using the Gastrointestinal Symptom Rating Scale (GSRS) * Anthropometric measurements: body weight, height, waist and hip circumference, BMI * Nutritional intake: 3-day dietary records

The study will be conducted at Bursa Yıldırım Doruk Hospital, General Surgery Clinic. Results will contribute to understanding the relationship between bariatric surgery and gut health, potentially helping to prevent postoperative complications.

Eligibility criteria

Qualifiers

Underwent Laparoscopic Sleeve Gastrectomy (LSG) within the last 1 month

Aged between 19-50 years

BMI ≥40 kg/m² or BMI ≥35 kg/m² with obesity-related comorbidities

Signed informed consent form

Disqualifiers

Did not undergo or is not planned to undergo LSG

Outside the age range of 19-50 years

Did not sign the informed consent form

BMI <40 kg/m² or BMI <35 kg/m² without obesity-related comorbidities

Trial design

Treatments tested in this trial

  • Clinical and Biochemical Assessment

Treatment groups

40 Participants
are divided into 1 treatment group

Locations

1
Bursa Yıldırım Doruk Hospital16310, BursaBursa, Turkey (Türkiye)

Sponsors and collaborators

Toros University

Lead sponsor